Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X MSCI Argentina ETF (ARGT) vs Eli Lilly And Co (LLY) Price & Performance

Global X MSCI Argentina ETF
Eli Lilly And Co

Price performance

Price movement over the last 24 hours

Key statistics

Global X MSCI Argentina ETF vs Eli Lilly And Co — how do they compare? Global X MSCI Argentina ETF trades at $95.07, while Eli Lilly And Co trades at $1,183.03 (market cap $1.06T). The key difference: Eli Lilly And Co pays a 0.58% dividend while Global X MSCI Argentina ETF pays none. Which is the better fit depends on your goals.

ARGTLLY
Sector
Broad Market / FactorHealth
52-Week High
$102.94$1.24K
52-Week Low
$67.55$625.65
Market Cap
$1.06T
Enterprise Value
$1.10T
Dividend Yield
0.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X MSCI Argentina ETF

ARGT (Global X MSCI Argentina ETF) trades at $95.07, up 3.08% with a neutral technical signal. The ETF shows bullish moving averages but mixed oscillators, with support at $92 and resistance at $93. Recent positive sentiment stems from Argentina's economic reforms under the Milei Administration, with Seeking Alpha upgrading the rating to buy citing 28% upside potential based on valuation re-rating opportunities.

The outlook appears constructive given Argentina's improving macroeconomic backdrop, though concentration risk in MercadoLibre and ongoing economic transition pose challenges. Wall Street sentiment has turned positive with institutional accumulation noted, but investors should monitor fiscal stabilization progress and inflation trends for sustained momentum.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,188.58, down 2.33% over 24 hours, but maintains a strong technical bullish trend with support near $1,172. The company demonstrates exceptional fundamental strength, with 2025 revenue surging to $65.18B and net income reaching $20.64B, driven by robust demand for its obesity and diabetes drugs. Recent news highlights a $400B market cap surge over the past year and positive analyst coverage, though valuation multiples remain elevated.

Outlook remains positive given Lilly's dominance in high-growth therapeutic areas and consistent earnings beats, but risks include intense competition from Novo Nordisk and rich valuations. Wall Street consensus is strongly bullish with a $1,340 price target, suggesting 13% upside from current levels, supported by institutional confidence in long-term growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X MSCI Argentina ETF

ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.

Read more on ARGT

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY